Abivax Posts Wider H1 2026 Net Loss, Sets Obefazimod NDA Filing for Ulcerative Colitis by End of 2026

Abivax SA (ABVX, ABVX.PA) reported a wider net loss for the first half of 2026 and said it plans to submit a New Drug Application for obefazimod in ulcerative colitis by the end of 2026, the clinical-stage biotechnology company announced on Sept. 22, 2026. The company also disclosed corporate appointments effective immediately. Abivax did not detail the specific loss figures in its milestone update. The company's shares trade on the Nasdaq under ABVX and on Euronext Paris under ABVX.PA.